Pirfenidone improves renal function and fibrosis in the post-obstructed kidney.
about
Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challengePirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failureSurvival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With PirfenidoneCytokine and anti-cytokine therapies in prevention or treatment of fibrosis in IBDMefunidone attenuates tubulointerstitial fibrosis in a rat model of unilateral ureteral obstructionIn vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion.Potential methods to prevent interstitial fibrosis in renal disease.Pirfenidone treatment of idiopathic pulmonary fibrosis.Atrial fibrosis and the mechanisms of atrial fibrillationThe multifaceted role of pirfenidone and its novel targets.Pirfenidone: an anti-fibrotic therapy for progressive kidney disease.Transplant renal artery stenosis: clinical manifestations, diagnosis and therapy.Therapeutic targets for treating fibrotic kidney diseasesAntifibrotic therapy in simian immunodeficiency virus infection preserves CD4+ T-cell populations and improves immune reconstitution with antiretroviral therapy.Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy.Pirfenidone inhibits transforming growth factor-β1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19.Emerging drugs for idiopathic pulmonary fibrosis.Therapeutic targets in the treatment of allograft fibrosis.Therapeutic potential of TGF-beta inhibition in chronic renal failure.TGF-β signaling in the kidney: profibrotic and protective effectsPirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses.Current and future anti-fibrotic therapies for chronic liver disease.Renal tubulointerstitial fibrosis: common but never simple.Fibrogenesis in kidney transplantation: potential targets for prevention and therapy.Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.Pathophysiological Mechanisms of Renal Fibrosis: A Review of Animal Models and Therapeutic Strategies.Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis.Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β.Potential approaches to reverse or repair renal fibrosis.The myofibroblast, a key cell in normal and pathological tissue repair.Available and incoming therapies for idiopathic focal and segmental glomerulosclerosis in adults.Effect of interleukin-10 and platelet-derived growth factor on expressions of matrix metalloproteinases-2 and tissue inhibitor of metalloproteinases-1 in rat fibrotic liver and cultured hepatic stellate cells.Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats.Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity.Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration.Duplex-Doppler long-term follow-up of renal transplant artery stenosis: case controlled study.Resveratrol as a therapeutic agent for renal fibrosis induced by unilateral ureteral obstruction.Pirfenidone exerts a suppressive effect on CCL18 expression in U937-derived macrophages partly by inhibiting STAT6 phosphorylation.Pirfenidone suppresses MAPK signalling pathway to reverse epithelial-mesenchymal transition and renal fibrosis.
P2860
Q24652737-B8D521EB-2127-4261-965A-40C2BF13A969Q24684669-A4415334-DCE1-45FA-9A3D-D8FD2E34CBA0Q24804516-70B738EB-3E3F-4E7C-AE2F-3A6EEB72B727Q26740540-2993CD96-3F5D-471B-BAD9-8E5D7F5B429DQ28547858-AD0DDCA6-6604-4AE9-9413-8474780A41AFQ34088175-D7818E26-C1C6-4456-91EE-274FCBB1E87AQ34481843-A26B9BB8-CA76-4EFD-ADF3-3E680FE80C49Q34574174-4EE209E6-CF50-414E-AD1B-4576B88C6DE6Q34576855-E9A7300F-EFC4-4D6A-9F4B-C2AB279EACA2Q34623073-C9B9D08E-EF94-4768-8306-EBEB593DF409Q34680788-C2DB62EA-D1C1-4251-8004-599463726A33Q35026504-5E268AD1-D8EE-43A3-886B-63809B2720CDQ35079607-A6E2B0CD-BDC4-4466-9B88-BA2043C2C408Q35102598-4CE23AF0-00BE-49B4-B9D6-E9957CDF9F06Q35841561-616824E7-22A3-40BC-8FE3-EAA6BE6C760DQ35919077-068F0254-7909-4697-82F4-ED2A8E87D3DBQ36302828-2430D448-F5E4-4387-BFAF-3ADA9247F474Q36447581-CF644E8C-1ECD-42D8-9B73-DAF93A61CA4EQ36739752-9A642A13-9318-424C-B846-98863BD66DDCQ36775661-9076C912-9217-4F23-9209-D2F30148BF49Q37305376-51BB318C-65E9-47FA-A757-98ED280881F4Q37317654-28753359-F9E1-4849-A21B-F4465D834970Q37368710-283989D2-ED71-468F-A645-A921D8B5DE61Q37638064-77FFC975-905A-4745-8431-6AA11F607716Q37686160-96E7F8BD-E9B7-42CB-ABF6-2A424442EA0EQ37705263-07F6AFD4-9083-48FF-9DE1-0C2C313B487BQ37708036-3EB8406C-CADC-4034-A481-596B9DFAFF84Q37762829-1C345FEE-0B56-4D52-86E8-3C2700148A14Q37924999-B1DA5F2E-5983-4299-8040-1C46F4805651Q38186986-484E5759-EA8A-4140-96CB-BFC2C0EC98B2Q38673061-B49340AF-8751-416F-A9F5-2CBBD4634A4EQ38805701-BB3A6444-FC17-4F73-9104-999BB5C427AFQ42035241-281E274C-6822-4983-AE5D-014C17B8BCADQ43650678-D330B91E-983D-4CB8-84C2-458773978079Q44051276-62CCB7C4-A69D-4500-BED6-B295E7039D51Q44063009-C8199AB8-DDC7-4C1C-B450-40272FF48531Q46556713-91AA4601-E6FA-4DBD-8AB0-A436203AC3D9Q46979246-EB10BD45-8438-4DCD-A037-483C8C7506FBQ51359224-A314E2AE-7CBA-49B0-937E-659B41D6F8CFQ51728385-7A67B428-4DB4-4CDD-8DE2-84CD12EFC713
P2860
Pirfenidone improves renal function and fibrosis in the post-obstructed kidney.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Pirfenidone improves renal function and fibrosis in the post-obstructed kidney.
@ast
Pirfenidone improves renal function and fibrosis in the post-obstructed kidney.
@en
Pirfenidone improves renal function and fibrosis in the post-obstructed kidney.
@nl
type
label
Pirfenidone improves renal function and fibrosis in the post-obstructed kidney.
@ast
Pirfenidone improves renal function and fibrosis in the post-obstructed kidney.
@en
Pirfenidone improves renal function and fibrosis in the post-obstructed kidney.
@nl
prefLabel
Pirfenidone improves renal function and fibrosis in the post-obstructed kidney.
@ast
Pirfenidone improves renal function and fibrosis in the post-obstructed kidney.
@en
Pirfenidone improves renal function and fibrosis in the post-obstructed kidney.
@nl
P2093
P1433
P1476
Pirfenidone improves renal function and fibrosis in the post-obstructed kidney.
@en
P2093
P304
P356
10.1046/J.1523-1755.1998.00962.X
P407
P577
1998-07-01T00:00:00Z
P5875
P6179
1023097532